Vertex Pharmaceuticals Incorporated vs Exxon Mobil Corporation — how do they compare? Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B), while Exxon Mobil Corporation trades at $167.14 (market cap $692.86B). The key difference: Exxon Mobil Corporation is far larger — about 5.4× Vertex Pharmaceuticals Incorporated's market cap, and Exxon Mobil Corporation pays a 2.45% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vertex Pharmaceuticals Incorporated for 120 Days and Exxon Mobil Corporation for 99 Days on average.
| VRTX | XOM | |
|---|---|---|
Market Cap | $127.55B | $692.86B |
Volume | 1,487,944 | 13,225,996 |
Sector | Health | Energy |
52-Week High | $557.96 | $171.52 |
52-Week Low | $407.37 | $110.64 |
Typical Hold Time | 120 Days | 99 Days |
Enterprise Value | $121.68B | $724.64B |
Dividend Yield | — | 2.45% |
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
ExxonMobil (XOM) trades at $168.56, up 2.48% with strong technical momentum and bullish moving average signals. The company maintains solid profitability with 9.07% net margin and 12.55% ROE, though revenue declined to $323.91B in 2025. Recent news highlights potential Venezuela investment and Guyana/Permian expansion, while analyst consensus shows 36% buy ratings with $168.08 price target.
XOM presents a balanced opportunity with operational strength and strategic growth initiatives, though faces headwinds from declining revenue trends and geopolitical risks. The stock's current valuation at 21.11 P/E appears reasonable given cash flow generation, but investors should monitor execution on production targets and oil price volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →